Log in to search using one of your social media accounts:

 

Auris Health, Ethicon ’ s NeuWave ink robot-assisted bronchoscope ablation dev deal

Auris Health, previously known as Auris Surgical Robotics, said today it inked a cooperative development and commercialization deal with Johnson &Johnson (NYSE:JNJ) division Ethicon’s NeuWave Medical subsidiary looking to develop systems for the robotically-assisted bronchoscopic ablation of lung lesions. Through the agreement, both companies will help develop an integrated system for robotic control, navigation and application of bronchoscope-delivered microwave ablation. The bronchoscope in development will be equipped with a small camera and accessory channel to allow tools to enter the lungs through the mouth, Auris said. “For those treating people with suspicious nodules in the lung, the holy grail is to one day be able to detect and treat the disease in a single procedure. When this option becomes a reality, we may see many patients seek early screening and minimally invasive treatment,” Dr. Kazuhiro Yasufuku of the University of Toronto said in a prepared release. The development deal also covers tech optimization and procedure development, Redwood City, Calif.-based Auris said. “From the beginning, our vision has been to create a platform capable of enabling advanced diagnosis and therapy for a spectrum of disease, using the least-invasive approach. We are honored to have Ethicon as a partner. Through this collaboration, we believe we are taking a significant first step together toward making the goal of diagnosing and treating lung ca...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Endoscopic / Arthroscopic Respiratory Robotics aurishealth Ethicon johnsonandjohnson NeuWave Medical Inc. Source Type: news

Related Links:

Followers of the Undoctored and Wheat Belly books and lifestyle understand a basic truth in logic: Just because something is less bad does not necessarily make it good. Low-tar cigarettes have less of the toxic compounds that leave the brown residue–“tar”–after tobacco is burned, but smoking low-tar cigarettes does not reduce risk for lung cancer, mouth/throat cancer, or cardiovascular disease. From Stanford.edu  on the impact of tobacco advertising: Claims of low ‘tar,’ less ‘tar,’ or even lowest ‘tar’ have been circulating in cigarette advert...
Source: Wheat Belly Blog - Category: Cardiology Authors: Tags: Grain Free Lifestyle News & Updates blood sugar diabetes diy health Dr. Davis grain-free grains healthy whole-grains low-carb low-fat undoctored wheat wheat belly Wheat Belly Total Health Source Type: blogs
This article is protected by copyright. All rights reserved. PMID: 29758087 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
Abstract A rapid and sensitive LC-MS/MS method for therapeutic drug monitoring oral vinorelbine (VRL) metronomic anticancer chemotherapy has been developed and validated. Analysis of VRL and its main active metabolite 4-O-deacetylvinorelbine (M1) was performed in whole blood matrix. Both analytes were extracted by protein precipitation and separated on an Onyx monolith C18, 50 x 2 mm column then quantified by positive electrospray ionization and multiple reaction monitoring mode. The LLOQ was 0.05 ng/mL for both VRL and M1. Linearity was up to 25 ng/mL with R2 ≥ 0.994. The intra- and inter-assay precision was &...
Source: Biomedical Chromatography : BMC - Category: Biomedical Science Authors: Tags: Biomed Chromatogr Source Type: research
Conclusions These findings might help explain the higher rural cancer mortality rates and provide additional evidence to support targeted interventions.
Source: American Journal of Preventive Medicine - Category: International Medicine & Public Health Source Type: research
Recent multi-institutional observational studies suggest that stereotactic body radiation therapy (SBRT) and chemotherapy for inoperable T1-2N0M0 small cell lung cancer (SCLC) appears safe and effective. There is no information available about how these patients compare to operable patients who receive surgery followed by chemotherapy, as recommended by national guidelines.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Oral Abstract Source Type: research
We sought to compare the toxicity and efficacy of stereotactic body radiotherapy (SBRT) versus stereotactic body proton therapy (SBPT) for high-risk medically inoperable early-stage non-small cell lung cancer (NSCLC).
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Oral Abstract Source Type: research
Immune checkpoint inhibitors (ICIs) are commonly used for treatment of advanced stage non-small cell lung cancer (NSCLC) and numerous clinical studies are examining combinations of ICIs with radiotherapy (RT). Standard-of-care response assessment is CT imaging, which is typically performed no earlier than 2-3 months after treatment initiation due to delayed radiographic responses and occasional pseudoprogression. Improved methods of response assessment would be useful clinically and in trials combining ICIs and RT.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Oral Abstract Source Type: research
Optimal treatment selection for clinical Stage I non-small cell lung cancer (NSCLC) patients currently involves consideration of an individual ’s comorbidities and functional status. Pre-treatment quality of life (QoL) data for this population has been limited. Our goal was to prospectively compare pre-treatment QoL outcomes between Stage I NSCLC patients receiving either stereotactic body radiation therapy (SBRT) or surgical resection, as QoL may correlate with patient satisfaction and post-treatment outcomes.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Oral Abstract Source Type: research
Rationale: Acute thrombosis has not been reported in the literature so far in lung cancer patients as an immune-related adverse event (irAE) associated with PD-1 pathway inhibitors. Patients concerns: Here, we for the first time present two NSCLC (non-small cell lung cancer) patients suffering from acute thrombosis as a pembrolizumab-induced irAE. Immediate treatment with continuous heparin infusion improved their symptoms and enabled them to continue pembrolizumab administration. Methods: Ethical approval was given by the ethics committee of Osaka International Cancer Institute and the informed consents were given...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
ConclusionThis combined regimen shows efficacy and a manageable safety profile. PFS and OS outcomes are encouraging and warrant further research.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
More News: Arthroscopy | Bronchoscopy | Cancer | Cancer & Oncology | Endoscopy | Lung Cancer | Medical Ethics | Oral Cancer | Respiratory Medicine